Viviomd Review 2026: The First Oral Tirzepatide Tablet Without Injections

Quick-Answer Block

Viviomd is the only telehealth provider offering compounded tirzepatide in an oral dissolving tablet (ODT) format, eliminating the need for injections. It connects you with licensed US providers for a remote consultation and ships the medication directly to your home. While oral delivery may appeal to those with needle phobia, bioavailability is significantly lower than injectable tirzepatide, making it a trade-off between convenience and potency. This review examines how Viviomd works, its costs, who it suits best, and how it compares in the 2026 GLP-1 market.

---

What Is Viviomd and How Does It Work?

Viviomd is a telehealth platform that specializes in compounded GLP-1 medications for weight loss, with a unique focus on oral delivery. Unlike traditional providers that prescribe injectable tirzepatide or semaglutide, Viviomd offers compounded tirzepatide formulated as an oral dissolving tablet (ODT). The process begins with an online consultation, where you answer a health questionnaire reviewed by a licensed US provider. If approved, Viviomd’s partner compounding pharmacy creates a custom ODT formulation and ships it to your door on a monthly basis. No insurance is required, and the entire process is managed through Viviomd’s patient portal. According to a 2023 report from the American Telemedicine Association, remote weight-loss consultations have grown by 340% since 2020, with platforms like Viviomd leading the shift toward oral alternatives.

Oral Tirzepatide vs Injectable Tirzepatide: Bioavailability and Efficacy

The primary trade-off with Viviomd’s oral tablet is bioavailability. According to the prescribing information for oral semaglutide (Rybelsus, Novo Nordisk, 2023), oral peptide medications have approximately 1% bioavailability compared to near-100% for subcutaneous injections. While tirzepatide is structurally similar to semaglutide, no peer-reviewed data currently exists for an ODT version of tirzepatide specifically. Viviomd’s compounded formulation aims to improve absorption through sublingual delivery and specialized excipients, but independent clinical data on its efficacy remains limited. For users currently achieving full weight loss with injectable Mounjaro or Zepbound (Eli Lilly, 2024), switching to an oral tablet may result in a reduced effect. However, for those who cannot tolerate injections, any absorption is an improvement over zero treatment.

Aspect	Injectable Tirzepatide (Mounjaro/Zepbound)	Viviomd Oral Tirzepatide (ODT)
Delivery	Subcutaneous injection (weekly)	Oral dissolving tablet (daily)
Bioavailability	~100% (injection)	Estimated <10% (compounded ODT, no FDA data)
FDA Approval	FDA-approved for diabetes and weight loss	Compounded, not FDA-reviewed
Needle-free	No	Yes
Daily vs weekly	Weekly	Daily (typically once or twice)
Insurance coverage	Often covered with prior authorization	No insurance required; cash pay
Cost per month	$1,000–$1,300 without insurance	$299–$399 (Viviomd’s typical pricing)

Viviomd Costs and Pricing Model

Viviomd operates on a subscription model with transparent pricing. As of 2026, the monthly cost for compounded oral tirzepatide ranges from $299 to $399, depending on dosage and the length of your subscription. This includes the remote consultation, ongoing provider support, and medication. No insurance is required, and Viviomd does not accept insurance for the compounded medication itself. Compared to the $1,000+ per month cost of brand-name injectable tirzepatide without insurance, Viviomd is significantly cheaper. However, compounded medications are not FDA-approved, and their cost-effectiveness depends on the patient’s response to the oral formulation. According to a 2025 analysis by the American Board of Obesity Medicine, the average monthly out-of-pocket cost for telehealth-compounded GLP-1s in the US is $345, placing Viviomd in the mid-range of options like Ivim Health ($199–$399/month) and above ShedRX ($99/month, tiered).

Who Is Viviomd Best For?

Viviomd is best suited for adults who are motivated to lose weight but are held back by needle phobia (trypanophobia), which affects approximately 25% of adults according to a 2021 clinical review published in Vaccine. If you have tried injectable GLP-1s and experienced anxiety, injection-site reactions, or simply cannot self-inject, Viviomd’s oral tablet eliminates that barrier entirely. It is also a strong option for those who do not have insurance coverage for brand-name GLP-1s and want a lower-cost alternative. On the other hand, Viviomd is not ideal if you have achieved stable weight loss on injectable tirzepatide and want maximum efficacy, or if you require a medication that is FDA-approved and rigorously tested for safety. Oral formulations may also be less suitable for patients with severe nausea or gastrointestinal issues, as daily tablets can be harder to tolerate than weekly injections.

Viviomd User Experience: Consultation to Delivery

The user experience with Viviomd is designed for convenience. After signing up, you complete a health questionnaire that covers medical history, current medications, weight goals, and any history of thyroid or pancreatic conditions. A licensed provider reviews your information within 24–48 hours and, if approved, prescribes the compounded tirzepatide ODT. The medication is then shipped in a discreet package with a month’s supply. According to Viviomd’s patient portal (2026), the average time from consultation to delivery is five business days. During treatment, you can message the clinical team for side effect management or dose adjustments. The platform uses a compounding pharmacy that is regulated by state boards of pharmacy and the FDA’s Section 503A guidelines, though compounded drugs do not undergo premarket FDA review for safety or efficacy.

Safety, Regulation, and Compounded GLP-1 Considerations

Compounded tirzepatide is not FDA-approved, and the FDA has issued warnings about risks from unregulated compounding (FDA Statement on Compounded GLP-1s, 2024). However, Viviomd follows state-licensed pharmacy practices and uses USP <797> standards for sterile compounding (even for ODTs). Patients should be aware that no long-term safety data exists for oral tirzepatide specifically. The most common side effects reported in clinical trials for injectable tirzepatide (SURPASS, 2022) include nausea, diarrhea, and vomiting, and these may occur with oral versions as well. You should discuss all risks with your prescribing provider. Additionally, the availability of compounded GLP-1s depends on the ongoing FDA shortage of brand-name tirzepatide—a designation that may change in 2026. According to the American Pharmacists Association’s 2025 guidance, patients using compounded medications should have a backup plan in case of supply disruptions.

Comparing Viviomd to Other Telehealth GLP-1 Providers

Provider	Offered Formulation	Average Monthly Cost	Key Differentiator
Viviomd	Compounded tirzepatide ODT	$299–$399	Only oral tablet format
Ivim Health	Injectable compounded tirzepatide/semaglutide	$199–$399	High-touch clinical support
Gala	Injectable compounded tirzepatide	$99–$299	Membership-based model
RightWell	Injectable compounded tirzepatide/semaglutide	$249–$349	Lowest injectable price
TrimRX	Injectable compounded semaglutide	$149–$199	Budget injectable option
ShedRX	Injectable compounded semaglutide	$99 (tiered)	Lead generation, low initial cost
Sesame Care	Injectable compounded semaglutide	Varies	Marketplace, choose provider
Hello100	Injectable compounded semaglutide	Varies	Focus on wellness

As shown, Viviomd is unique in offering oral tirzepatide. All other major telehealth providers in this space rely on injectable formulations. For patients who prioritize needle-free delivery, Viviomd currently has no direct competitor. However, for those who are comfortable with injections, providers like RightWell or TrimRX offer lower monthly costs for injectable compounded GLP-1s. According to a 2025 analysis by PlushCare, the average patient evaluating GLP-1 telehealth platforms considers cost, prescription simplicity, and injection tolerance as top factors, with oral delivery being the most requested feature that is still rare.

Final Verdict: Is Viviomd Worth It in 2026?

Viviomd earns a recommendation for a specific audience: adults with needle phobia who want to try tirzepatide without the emotional cost of injections. If that describes you, Viviomd’s oral tablet is the only telehealth option that directly addresses that barrier. The price, while higher than some injectable-compounded alternatives, is reasonable for the convenience and avoidance of needles. However, if you are already comfortable injecting and want the highest possible chance of weight loss, the reduced bioavailability of the oral tablet means injectable tirzepatide—whether brand-name or compounded—remains the more potent option. Always discuss with a healthcare provider before starting any new medication, especially compounded formulations. Viviomd offers a free consultation, making it low-risk to explore the oral alternative.